Table 1

Baseline Characteristics (Primary Population)

Prasugrel
10 mg/QD MD
(n = 27)
Ticagrelor
180 mg LD/90 mg/bid MD
(n = 25)
Ticagrelor
90 mg/bid MD
(n = 27)
p Value
Age, yrs57 ± 6.954.8 ± 10.557 ± 70.551
Men21 (77.8)21 (84)20 (74.1)0.681
Body mass index, kg/m230.2 ± 4.432.7 ± 930.2 ± 6.10.335
Duration of prasugrel therapy, days20 (15–31)20 (14–37)19 (15–40)0.925
Race0.223
 White19 (70.4)20 (80)16 (59.3)
 African-American8 (29.6)4 (16)11 (40.7)
 Hispanic0 (0)1 (4)0 (0)
Hypertension21 (77.8)21 (84)19 (70.4)0.457
Dyslipidemia17 (63)18 (72)18 (66.7)>0.999
Smoking20 (74)19 (76)21 (77.8)0.767
Diabetes mellitus10 (37)10 (40)16 (59.2)0.371
PAD2 (7.4)2 (8)2 (7.4)0.999
Prior CABG2 (7.4)4 (16)4 (14.8)0.371
Medications
 Beta-blockers27 (100)25 (100)27 (100)>0.999
 ACEI/ARB17 (63)20 (80)24 (88.9)0.053
 Statins25 (92.6)23 (92)25 (92.6)0.622
 PPIs4 (14.8)6 (24)9 (33.3)0.553
 CCB6 (22.2)2 (8)4 (14.8)0.418
 Nitrates9 (33.3)7 (28)10 (37)0.772
 OAD6 (22.2)9 (36)13 (48.1)0.278
 Insulin2 (7.4)4 (16)6 (22.2)0.338
Creatinine, mg/dl0.9 ± 0.20.8 ± 0.20.9 ± 0.20.343
Hemoglobin, g/dl13.7 ± 1.313.4 ± 1.212.9 ± 1.40.130
Hematocrit, %40.4 ± 439.6 ± 3.138 ± 40.083
Platelet count, 1,000/mm3207 ± 45.9243 ± 63.7239 ± 810.107

Values are mean ± SD, median (interquartile range), and n (%).

ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CABG = coronary artery bypass graft; CCB = calcium-channel blocker; LD = loading dose; MD = maintenance dose; MI = myocardial infarction; OAD = oral antidiabetic drug; PAD = peripheral artery disease; PPIs = proton pump inhibitors.